PIPER SANDLER COMPANIES 8-K

What Happened
Piper Sandler Companies announced that, effective February 4, 2026, the Board elected Stuart M. Essig as a director, increasing the board size from nine to ten. Mr. Essig was appointed to the Board’s Audit Committee and will serve an initial term expiring at the Company’s 2026 annual meeting of shareholders. The company issued a press release on February 4, 2026, disclosing the appointment.

Key Details

• Director: Stuart M. Essig elected to Piper Sandler’s Board, term through the 2026 annual meeting.
• Committee: Appointed to the Audit Committee.
• Compensation: Will participate in the 2026 non-employee director program — pro‑rated $100,000 cash retainer, $60,000 initial equity grant, and a $150,000 annual equity grant after the 2026 annual meeting.
• Background & conflicts: Former CEO (1997–2012) and long‑time chairman of Integra LifeSciences; director of IDEXX Laboratories since 2017. No related person transactions or selection arrangements were reported.

Why It Matters
The addition of Mr. Essig expands the board and brings experience from medical technology and public company leadership, which may influence governance and oversight—particularly on the Audit Committee, which oversees financial reporting and controls. The disclosed director compensation and statement of no related‑party transactions provide transparency on governance and potential conflicts for investors evaluating board independence and oversight.